Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETHOS Japan: PT010 vs PT003 vs PT009 in COPD Exacerbations
jRCT2080224019Phase 3Completed
- Sponsor
- Pearl Therapeutics
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of BGF MDI HFO, BEVESPI AEROSPHERE and budesonide + formoterol fumarate in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Pearl Therapeutics. Primary endpoint: COPD exacerbations over 52 weeks. Started Aug 2018; status: completed.
02
Drugs
BGF MDI HFOBEVESPI AEROSPHEREbudesonide + formoterol fumarate
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on jRCT2080224019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224019.